title: [Biological effects of interferon, produced by recombinant bacteria of the probiotic preparation subalin].
abstract: The present review deals with the analysis of biological and functional activities of recombinant bacteria Bacillus subtilis IF-alpha 2335 are producing a human interferon. The interferon-producing bacteria are constructed on a basis commercial probiotic strain B.subtilis 2335, carrying a recombinant plasmid pMBM 105 with the gene of human alpha-2 interferon. The implementation of the recombinant strain in the preparation probiotic, received a designation "Subalin", necessitates to verify a number of immunologic activities and to perform successive protective effects. Interferon, synthesized by recombinant bacteria shows the activity on macroorganism at oral and rectal application of preparation. Subalin was shown antivirus and antitumor activity and preservation by recombinat bacteria of antagonistic properties. The mechanisms of the positive effect of subalin were considered: this effect was shown to be due to the action of interferon excreted by recombinant bacteria into the mucous of different biotopes of host.
authors.affiliation: State Research Center Vector, Koltsovo, Novosibirsk Region.
authors.forename: V A
authors.initials: VA
authors.lastname: Beliavskaia
authors.forename: N V
authors.initials: NV
authors.lastname: Cherdyntseva
authors.forename: V M
authors.initials: VM
authors.lastname: Bondarenko
authors.forename: N V
authors.initials: NV
authors.lastname: Litviakov
mesh_terms: D000284:Administration, Oral; D000285:Administration, Rectal; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001412:Bacillus subtilis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001685:Biological Factors / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000235:genetics / Q000276:immunology*; D009369:Neoplasms / Q000628:therapy; D019936:Probiotics / Q000008:administration & dosage*; D011994:Recombinant Proteins; D011995:Recombination, Genetic; D014777:Virus Diseases / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001685:Biological Factors; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; C112120:subalin